Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenleuton SCHEMBL31539081 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL13140097 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9046388 | 0.91 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9048463 | 0.90 | ALOX5 (0.84) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9047251 | 0.90 | ALOX5 (0.84) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9046519 | 0.89 | ALOX5 (0.83) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL9047878 | 0.88 | ALOX5 (0.78) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9047572 | 0.88 | ALOX5 (0.78) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9049055 | 0.87 | ALOX5 (0.79) | ALOX5EPHX2MAPTMEN1ALDH1A1 | |
| SCHEMBL9047950 | 0.86 | ALOX5 (0.83) | ALOX5EPHX2MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| EP-3345897-A1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2018-07-11 | — | — | EP | claimed |
| US-10011584-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2018-07-03 | — | — | US | claimed |
| US-9951042-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl] pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2018-04-24 | — | — | US | claimed |
| EP-2697215-B1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-22 | — | — | EP | claimed |
| US-20170121306-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | SOLVIAS AG (CH) | 2017-05-04 | — | — | US | claimed |
| EP-3137452-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2017-03-08 | — | — | EP | claimed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-0850217-B1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 2000-04-05 | — | — | EP | claimed |
| EP-0850217-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | Abbott Laboratories (US) | 1998-07-01 | — | — | EP | claimed |
| US-5714633-A | Process for the preparation of arylalkynyl-N-hydroxyurea derivatives having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1998-02-03 | — | — | US | claimed |
| WO-1997010206-A1 | PROCESS FOR THE PREPARATION OF ARYLALKYNYL-N-HYDROXYUREA DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1997-03-20 | — | — | WO | claimed |
| EP-0540673-B1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1996-10-16 | — | — | EP | claimed |
| US-5476873-A | Inhibit biosynthesis of leukotrienes | ABBOTT LABORATORIES (US) | 1995-12-19 | — | — | US | claimed |
| EP-0540673-A4 | — | — | 1994-04-27 | — | — | EP | claimed |
| EP-0540673-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001682-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011584-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | CYP1B1, CYP3A5, CYP1A1 | ALOX5 254/4885EPHX2 1284/4885MAPT 1298/4885 |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ALOX5 2744/4885EPHX2 972/4885MAPT 1043/4885 |
| US-20170121306-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | UGT1A1, CYP3A5, CYP2D6 | ALOX5 275/4885EPHX2 772/4885MAPT 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.